fbpx Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders - Videos | JLABS

Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders

07/01/2021 JLABS @ BE
02:28:44
Neuroimmunology_ Potential for Novel Therapeutics for CNS Disorders

Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders

The successes of therapeutics targeting inflammatory mechanisms in relapsing and remitting multiple sclerosis have led to neuroimmunology emerging as an important new paradigm in central nervous system (CNS) disorders.1 In neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease, human disease genetics strongly implicate several inflammatory pathways such as microglial signaling and complement.2 Moreover, recent research implicates inflammation in psychiatric disorders such as schizophrenia and major depressive disorder.3

The field holds great promise for the development of impactful novel therapeutics to treat several CNS disorders of high unmet medical need. Current challenges focus on generating robust therapeutic hypotheses for neuroinflammatory disorders, patient stratification and drug discovery challenges to develop safe CNS penetrant molecules. However, new data emerging from advanced genomics and big data analytics is helping the field better understand the challenges and navigate the roles of various inflammatory processes in several CNS indications. This research is bolstered by exciting findings from human cell and preclinical transgenic models, enabling further detailed understanding of disease biology.

While past pharmaceutical company investment has been thwarted by the complexities of CNS disorders, a vibrant investor environment is now supporting exciting new companies with drug discovery programmes for a range of neuroimmunology targets. Given the advances in this field, Johnson & Johnson Innovation, in collaboration with Janssen Neuroscience, is seeking to gather industry-leading entrepreneurs, biotechs and academic researchers for a discussion on harnessing the next wave of science and innovation in neuroimmunology.

  • Dobson and Giovannoni Eur J Neurol. 2019 26: 27-40
  • Crehan et al. 2012. Int J Alzheimer Dis doi: 10.1155/2012/983640
  • Bauer and Teixeira 2021 Neuroimmunomodulation doi: 10.1159/000515594

Check out more On-Demand Webinars

Please note that this webinar was originally run on 06/30/2021.

You are watching a rebroadcast of the webinar. There will not be a live Q&A session following the presentation. If you have any questions for the speakers, please email  [email protected]

DISCLAIMER: The information on this webpage, including in the videos, is proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (“JJI”) and is for informational purposes only.  This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson or its affiliates.  The information presented in the videos is specific and applicable to region in which the original presentation took place. Many videos contain information from, or sessions given by, third parties. Please note that only those third parties that provide this information are responsible for it. By providing this information, JJI does not endorse these third parties or any of the information provided in these videos, and JJI makes no representations, warranties, or assurances, express or implied, as to the content or the information presented and is not responsible for any use of this information by you.                   


Related content